After ongoing difficulties at a manufacturing plant that supplies sterile injectable medicines for hospitals around the U.S., Pfizer (PFE) has a bit of good news: Full production is expected to resume next week after maintenance sidelined some operations, according to an internal memo.
Even so, regular shipments for some medications will ramp up over a period of months as product testing occurs, suggesting supplies for some drugs will remain hard to come by into 2019, according to the latest product availability report posted on the Pfizer website.
About the Author Reprints
